Search

Your search keyword '"SAADI, JOSÉ"' showing total 4 results
Start Over Author "SAADI, JOSÉ" Language spanish; castilian
4 results on '"SAADI, JOSÉ"'

1. Cáncer de endometrio

Author

Saadi, José M., Cortez, Juan Pablo, Odetto, Diego, Forestieri, Orlando Ángel, and Uranga, Alfredo

Subjects
cáncer de endometrio, síntomas, Medicina, factores de riesgo
Abstract

El cáncer de endometrio es, en la Argentina, el segundo cáncer en frecuencia del tracto genital, después del cáncer de cuello uterino. Es una neoplasia predominantemente de la posmenopausia, que se presenta en el 80 % de los casos con episodios repetidos de metrorragia. Es importante el asesoramiento sobre los síntomas o situaciones por las cuales deben consultar. A las mujeres posmenopáusicas se les debe advertir sobre la importancia de la consulta médica temprana ante la presencia de sangrados vaginales. En países desarrollados es el cáncer ginecológico más frecuente. La tasas de incidencia en estos países representan 14,7 casos/100.000 mujeres con una mortalidad de 2,3/100.000 mujeres. La mayoría de los casos no se pueden prevenir, pero la reducción de factores de riesgo puede disminuir la probabilidad de desarrollar la enfermedad. Es muy importante dar a conocer a todas las mujeres los factores de riesgo y síntomas del cáncer de endometrio., Facultad de Ciencias Médicas

Published
2022

2. [Treatment of advanced epithelial ovarian tumor. Hospital Italiano de Buenos Aires experience].

Author

Odetto D, Cortez JP, Saadi JM, Zamora LB, Riggi MC, Lamm M, and Perrotta MB

Subjects
Carcinoma, Ovarian Epithelial pathology, Carcinoma, Ovarian Epithelial therapy, Female, Hospitals, Humans, Neoadjuvant Therapy, Neoplasm Staging, Retrospective Studies, Treatment Outcome, Ovarian Neoplasms pathology, Ovarian Neoplasms therapy
Abstract

Ovarian cancer represents the third gynecological cancer in frequency in Argentina. There is a lack of information on this pathology in our country regarding the treatment and evolution of patients who suffer it. The aim of this study was to evaluate the perioperative and oncological results in patients with advanced epithelial ovarian tumor. We present a retrospective cohort in which we evaluated disease-free survival and overall survival in patients with epithelial ovarian tumor treated at the Hospital Italiano de Buenos Aires between June 2009 and June 2017. Of 170 patients included in the study, 72 (42.4%) received primary debulking surgery (CCP), while 98 (57.6%) received neoadjuvant therapy and interval surgery (CI). The optimal cyto-reduction rate was 75% and 79% respectively. No differences were found in perioperative outcomes, or in severe complications between the two groups. The median disease-free survival in the CCP group was 2.5 years (95% CI 1.6-3.1) while in the CI group it was 1.4 (95% CI 1.2-1.7) p < 0.001. The median overall survival was 5.8 years in CPP, and 3.5 years in CI. Faced with a meticulous selection by a group of experts, patients with advanced ovarian cancer treated with CCP present better oncological results than those who received neoadjuvant therapy and CI.

Published
2021

3. [Updated recommendations for venous thromboembolic prophylaxis in Argentina].

Author

Vazquez FJ, Korin J, Baldessari EM, Capparelli FJ, Gutierrez P, Pale C, Bocanegra F, Grand B, Vilaseca A, Penchasky D, González Alcantara MM, Prémoli MS, Tabares A, Wainsztein N, Odetto D, Vaccaro C, Martínez Aquino E, Cumpian O, Falabella V, García SA, Saadi J, Siccardi M, and Gandara E

Subjects
Adult, Argentina, Humans, Risk Assessment, Risk Factors, Anticoagulants administration & dosage, Practice Guidelines as Topic, Pre-Exposure Prophylaxis standards, Pulmonary Embolism prevention & control, Venous Thromboembolism prevention & control
Abstract

Venous thromboembolic disease (VTE) in hospitalized adults has high morbidity and mortality, is the origin of chronic complications and increased cost for the health system. Since the publication of recommendations for thromboprophylaxis in hospitalized patients in 2013, new alternatives and strategies have emerged, which motivated us to update our recommendations. Although there are different consensus and clinical practice guidelines, adherence to them is suboptimal. The different therapeutic alternatives for hospitalized adult patients (non-surgical, surgical non-orthopedic, with and without cancer, orthopedic an d pregnant) have been updated, paying particular attention to the drugs available in Argentina.

Published
2020

4. [Recommendations for the use of thromboprophylaxis in hospitalized patients with COVID-19 in Argentina].

Author

Vazquez FJ, Korin J, Baldessari EM, Capparelli FJ, Gutierrez P, Pale C, Bocanegra F, Grand B, Penchasky D, Gonzalez Alcántara MM, Prémoli MS, Tabares A, Wainsztein N, Odetto D, Vaccaro C, Martínez Aquino E, Cumpian O, Falabella V, Antuel García S, Saadi J, Siccardi M, and Gándara E

Subjects
Anticoagulants therapeutic use, Argentina, Betacoronavirus, COVID-19, Coronavirus Infections epidemiology, Coronavirus Infections therapy, Humans, Pandemics, Pneumonia, Viral epidemiology, Pneumonia, Viral therapy, SARS-CoV-2, Anticoagulants administration & dosage, Coronavirus, Inpatients, Thromboembolism prevention & control, Venous Thromboembolism prevention & control
Abstract

Although the incidence is uncertain, some case reports suggest that COVID 19 infection is associated with an increased risk of venous thromboembolism. We suggest starting prophylactic anticoagulant therapy for all patients hospitalized with a symptomatic infection with COVID-19, unless contraindicated, with enoxaparin 40 mg SC daily if creatinine clearance is greater than 30 ml/min.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results